Sea4Us Competitors and Similar CompaniesClear all
Sea4Us's competitors and similar companies include Kamada Pharmaceuticals, Travere Therapeutics, Sosei Heptares and GBT (Global Blood Therapeutics).
 Sea4Us Sea4Us is a biopharmaceutical company focused on the discovery and development of pharmaceutical drugs based on marine compounds. |  Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. |  Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. | ||
Founding Date | Founding Date 2013 | Founding Date 1990 | Founding Date 2011 | Founding Date 1990 | Founding Date 2012 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Budens, PT HQ | Locations Rehovot, IL HQ Beit Kama, IL | Locations San Diego, US HQ Dublin, IE | Locations Tokyo, JP HQ Dublin, IE Cambridge, GB London, GB | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB |
Employees | Employees 23 | Employees 420 | Employees 46293% increase | Employees 387 | Employees 352106% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 317 m | Valuation ($) 1.4 b | Valuation ($) 697 m | Valuation ($) 4.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $180.5m (FY, 2025) | Revenue (est.) $490.7m (FY, 2025) | Revenue (est.) ¥29.6b (FY, 2025) | Revenue (est.) $194.7m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods $72.1m (FY, 2025) | Cost of goods $10.3m (FY, 2025) | Cost of goods ¥7.3b (FY, 2025) | Cost of goods $3.3m (FY, 2021) |
Gross profit | Gross profit N/A | Gross profit $108.4m (FY, 2025) | Gross profit $480.4m (FY, 2025) | Gross profit ¥24b (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income $20.2m (FY, 2025) | Net income ($25.5m) (FY, 2025) | Net income (¥12.5b) (FY, 2025) | Net income ($303.1m) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 90m | Total funding raised $ 25m | Total funding raised $ 65m | Total funding raised $ 88.7m |
For sources of this data, please see the company profile
View Company Profiles
Kamada Pharmaceuticals
HQ
Rehovot, IL
Employees
420
Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
View companyTravere Therapeutics
HQ
San Diego, US
Employees
462
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View company
Sosei Heptares
HQ
Tokyo, JP
Employees
387
Sosei Heptares is a biopharmaceutical company that specializes in drug development.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View company